This trial is to study VX-121/tezacaftor/deutivacaftor, a drug combo for treating cystic fibrosis, in patients with a certain mutation.
- Cystic Fibrosis
3 Primary · 19 Secondary · Reporting Duration: From Day 1 up to Day 50
2 Treatment Groups
Part A: VX-121/TEZ/D-IVA
1 of 2
Part B: VX-121/TEZ/D-IVA
1 of 2
210 Total Participants · 2 Treatment Groups
Primary Treatment: VX-121/TEZ/D-IVA · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 1 - 11 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are investigators still looking for participants for this research project?
"Yes, an inspection of clinicaltrials.gov discloses that this trial is currently looking for participants. This specific study was posted on June 21st, 2022 and updated as recently as August 30th, 8/30/2022. 210 individuals are needed across 8 locations." - Anonymous Online Contributor
Does this research project consider applicants who are adults?
"The age bracket for patients that this study can accept begins at 1 year old and ends at 10 years old." - Anonymous Online Contributor
Could you give me an estimate of how many individuals are involved in this research project?
"In order to start this clinical trial, 210 eligible patients must enroll. These individuals can be recruited from several locations, such as Boston Children's Hospital in Boston, Massachusetts and UPMC Children's Hospital of Pittsburgh in Pittsburgh, Pennsylvania." - Anonymous Online Contributor
How many different hospitals are participating in this clinical trial?
"To make things more convenient for participants, this clinical trial is taking place at 8 locations. Those who live near Boston, Pittsburgh or Aurora will have a shorter distance to travel. However, there are also 8 other sites located in different cities." - Anonymous Online Contributor
Who does this study aim to target as potential participants?
"The ideal candidate for this study would be somebody with cystic fibrosis who is between 1 and 11 years old. They should also have at least one TCR mutation in the CFTR gene." - Anonymous Online Contributor
Are there any reported dangers of VX-121/TEZ/D-IVA to human beings?
"VX-121/TEZ/D-IVA is a phase 3 trial drug, which means that while there is some evidence of efficacy, mostly there is data backing up its safety. Power rates it as a 3 on their safety scale." - Anonymous Online Contributor